We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemours (CC) Raises Methylamines Prices in North America
Read MoreHide Full Article
The Chemours Company (CC - Free Report) announced a 10% hike in prices for all Methylamines, Dimethylformamide, Dimethylacetamide and Dimethyl Sulfate products sold in North America. The hike will be effective Jul 1, 2018 or as contracts permit.
Chemours is exposed to headwinds from higher costs for certain raw materials. Higher raw material costs hurt margins in its Chemical Solutions segment in the first quarter. It expects input cost pressure to continue for the rest of the year. However, the company has implemented price hikes for certain products, which is likely to offset the impact of higher raw material costs and drive margins.
Chemours’ shares moved up 8.3% over the past six months, outperforming the industry’s 3.6% dip.
Based on its solid first-quarter results and visibility into the balance of 2018, Chemours continues to expect adjusted EBITDA to be at the higher end of its earlier announced range of $1.7-$1.85 billion driven by sustained positive momentum across its businesses. It expects adjusted earnings per share to be in the band of $5-$5.75. Chemours expects to deliver further margin expansion throughout the balance of 2018.
The company is gaining from healthy demand for Ti-Pure titanium dioxide, sustained adoption of Opteon refrigerant and higher demand for fluoropolymers products.
FMC Corp has an expected long-term earnings growth rate of 14.3%. Its shares have moved up 15.1% in a year.
Westlake Chemical has an expected long-term earnings growth rate of 12.2%. Its shares have rallied 86.7% in a year.
Celanese has an expected long-term earnings growth rate of 8.9%. Its shares have gained 31% in a year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Chemours (CC) Raises Methylamines Prices in North America
The Chemours Company (CC - Free Report) announced a 10% hike in prices for all Methylamines, Dimethylformamide, Dimethylacetamide and Dimethyl Sulfate products sold in North America. The hike will be effective Jul 1, 2018 or as contracts permit.
Chemours is exposed to headwinds from higher costs for certain raw materials. Higher raw material costs hurt margins in its Chemical Solutions segment in the first quarter. It expects input cost pressure to continue for the rest of the year. However, the company has implemented price hikes for certain products, which is likely to offset the impact of higher raw material costs and drive margins.
Chemours’ shares moved up 8.3% over the past six months, outperforming the industry’s 3.6% dip.
Based on its solid first-quarter results and visibility into the balance of 2018, Chemours continues to expect adjusted EBITDA to be at the higher end of its earlier announced range of $1.7-$1.85 billion driven by sustained positive momentum across its businesses. It expects adjusted earnings per share to be in the band of $5-$5.75. Chemours expects to deliver further margin expansion throughout the balance of 2018.
The company is gaining from healthy demand for Ti-Pure titanium dioxide, sustained adoption of Opteon refrigerant and higher demand for fluoropolymers products.
Chemours Company (The) Price and Consensus
Chemours Company (The) Price and Consensus | Chemours Company (The) Quote
Zacks Rank & Other Stocks to Consider
Chemours currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks worth considering in the basic materials space are FMC Corporation (FMC - Free Report) , Westlake Chemical Corporation (WLK - Free Report) and Celanese Corporation (CE - Free Report) , each flaunting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
FMC Corp has an expected long-term earnings growth rate of 14.3%. Its shares have moved up 15.1% in a year.
Westlake Chemical has an expected long-term earnings growth rate of 12.2%. Its shares have rallied 86.7% in a year.
Celanese has an expected long-term earnings growth rate of 8.9%. Its shares have gained 31% in a year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>